Why it is on record
Long-standing British multinational pharmaceutical subsidiary; manufacturer of Panadol, Andrews Liver Salts, Ribena, Lucozade, Macleans and Sensodyne in the Nigerian market. Announced full exit on 3 August 2023 — the largest pharmaceutical multinational withdrawal from Nigeria in the Fourth Republic.
Record held
Largest multinational pharmaceutical exit from Nigeria (announced 3 August 2023, completed 2024).
Headquarters
Ilupeju, Lagos (pre-exit).
Key dates
- 1971Beecham of Nigeria incorporated.
- 2000Renamed GlaxoSmithKline Consumer Nigeria following GSK merger.
- 3 Aug 2023GSK announces termination of direct commercial presence in Nigeria; products to be distributed by third-party agents.
- 2024Direct operations wound down; distribution transferred.
Deep dive
GlaxoSmithKline Consumer Nigeria Plc — incorporated in 1971, NSE-listed — was the local arm of the British pharmaceutical and consumer-health giant. Its August 2023 announcement of the cessation of operations in Nigeria, the conversion to a third-party distribution model, and the eventual NGX delisting was the headline event of the 2023 multinational exit wave from Nigeria (alongside Procter & Gamble's exit and Unilever's product-portfolio rationalisation). GSK's exit is the central cautionary case of the FX and operating-environment crisis of the early Tinubu period.
Controversies & accountability
- · The August 2023 GSK exit was the most-discussed corporate withdrawal of the early Tinubu administration, alongside the simultaneous Procter & Gamble, Sanofi and Bayer (consumer) reorganisations — collectively cited as evidence of the foreign-exchange access crisis precipitated by the float of the naira.